0001145549-24-002777.txt : 20240124 0001145549-24-002777.hdr.sgml : 20240124 20240124130849 ACCESSION NUMBER: 0001145549-24-002777 CONFORMED SUBMISSION TYPE: NPORT-P PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20231130 FILED AS OF DATE: 20240124 DATE AS OF CHANGE: 20240124 PERIOD START: 20240831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Strategic Trust CENTRAL INDEX KEY: 0001873280 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: NPORT-P SEC ACT: 1940 Act SEC FILE NUMBER: 811-23723 FILM NUMBER: 24555485 BUSINESS ADDRESS: STREET 1: 7887 EAST BELLEVIEW AVE.,SUITE 1100 CITY: DENVER STATE: CO ZIP: 80111 BUSINESS PHONE: 212-951-0499 MAIL ADDRESS: STREET 1: 7887 EAST BELLEVIEW AVE.,SUITE 1100 CITY: DENVER STATE: CO ZIP: 80111 FORMER COMPANY: FORMER CONFORMED NAME: Kelly Strategic ETF Trust DATE OF NAME CHANGE: 20210719 0001873280 S000073961 Kelly CRISPR & Gene Editing Technology ETF C000231237 Kelly CRISPR & Gene Editing Technology ETF XDNA NPORT-P 1 primary_doc.xml NPORT-P false 0001873280 XXXXXXXX S000073961 C000231237 Strategic Trust 811-23723 0001873280 549300DBTMGXJIJI8N21 7887 East Belleview Ave. Suite 1100 Denver 80111 212-951-0499 Kelly CRISPR & Gene Editing Technology ETF S000073961 54930008LLNT6JJ4MO84 2024-08-31 2023-11-30 N 2587700.650000000000 1514.430000000000 2586186.220000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 N Biogen Inc W8J5WZB5IY3K0NDQT671 Biogen Inc 09062X103 56.000000000000 NS USD 13108.480000000000 0.5068652790 Long EC CORP US N 1 N N N Editas Medicine Inc 5299000AON4Q9NT2JE42 Editas Medicine Inc 28106W103 14406.000000000000 NS USD 151695.180000000000 5.8655938550 Long EC CORP US N 1 N N N First American Treasury Obliga 549300UU586IAH2B8H03 First American Treasury Obligations Fund 31846V328 4849.590000000000 NS USD 4849.590000000000 0.1875189792 Long STIV RF US N 1 N N N Illumina Inc SQ95QG8SR5Q56LSNF682 Illumina Inc 452327109 308.000000000000 NS USD 31400.600000000000 1.2141662405 Long EC CORP US N 1 N N N Novartis AG 5493007HIVTX6SY6XD66 Novartis AG N/A 812.000000000000 NS 79486.450000000000 3.0735006391 Long EC CORP CH N 1 N N N Verve Therapeutics Inc N/A Verve Therapeutics Inc 92539P101 9968.000000000000 NS USD 112439.040000000000 4.3476776394 Long EC CORP US N 1 N N N Sanofi SA 549300E9PC51EN656011 Sanofi SA N/A 910.000000000000 NS 84852.970000000000 3.2810077381 Long EC CORP FR N 1 N N N Sangamo Therapeutics Inc 2549006WMRKRC4G32Z67 Sangamo Therapeutics Inc 800677106 101500.000000000000 NS USD 43645.000000000000 1.6876201591 Long EC CORP US N 1 N N N Thermo Fisher Scientific Inc HCHV7422L5HDJZCRFL38 Thermo Fisher Scientific Inc 883556102 518.000000000000 NS USD 256803.680000000000 9.9298216816 Long EC CORP US N 1 N N N CRISPR Therapeutics AG 506700O6IRRIQLT3W370 CRISPR Therapeutics AG N/A 5698.000000000000 NS USD 380227.540000000000 14.7022490902 Long EC CORP CH N 1 N N N QIAGEN NV 54930036WK3GMCN17Z57 QIAGEN NV N/A 448.000000000000 NS USD 18439.680000000000 0.7130066604 Long EC CORP NL N 1 N N N Agilent Technologies Inc QUIX8Y7A2WP0XRMW7G29 Agilent Technologies Inc 00846U101 574.000000000000 NS USD 73357.200000000000 2.8365010776 Long EC CORP US N 1 N N N Allogene Therapeutics Inc N/A Allogene Therapeutics Inc 019770106 32998.000000000000 NS USD 77545.300000000000 2.9984422390 Long EC CORP US N 1 N N N Intellia Therapeutics Inc 5493002T5BCPE5DZC723 Intellia Therapeutics Inc 45826J105 7616.000000000000 NS USD 225662.080000000000 8.7256701878 Long EC CORP US N 1 N N N AbbVie Inc FR5LCKFTG8054YNNRU85 AbbVie Inc 00287Y109 728.000000000000 NS USD 103659.920000000000 4.0082156187 Long EC CORP US N 1 N N N Beam Therapeutics Inc N/A Beam Therapeutics Inc 07373V105 12306.000000000000 NS USD 345552.480000000000 13.3614693841 Long EC CORP US N 1 N N N Bristol-Myers Squibb Co HLYYNH7UQUORYSJQCN42 Bristol-Myers Squibb Co 110122108 854.000000000000 NS USD 42170.520000000000 1.6306064766 Long EC CORP US N 1 N N N Caribou Biosciences Inc N/A Caribou Biosciences Inc 142038108 21784.000000000000 NS USD 127872.080000000000 4.9444266237 Long EC CORP US N 1 N N N First American Government Obli 549300R5MYM6VZF1RM44 First American Government Obligations Fund 31846V336 4849.590000000000 NS USD 4849.590000000000 0.1875189792 Long STIV RF US N 1 N N N Precision BioSciences Inc 549300I5QGRS3BLHZH41 Precision BioSciences Inc 74019P108 62664.000000000000 NS USD 22251.990000000000 0.8604171590 Long EC CORP US N 1 N N N Prime Medicine Inc N/A Prime Medicine Inc 74168J101 21546.000000000000 NS USD 156423.960000000000 6.0484414769 Long EC CORP US N 1 N N N 2seventy bio Inc N/A 2seventy bio Inc 901384107 24724.000000000000 NS USD 45244.920000000000 1.7494842270 Long EC CORP US N 1 N N N Vertex Pharmaceuticals Inc 54930015RAQRRZ5ZGJ91 Vertex Pharmaceuticals Inc 92532F100 112.000000000000 NS USD 39738.720000000000 1.5365761248 Long EC CORP US N 1 N N N Regeneron Pharmaceuticals Inc 549300RCBFWIRX3HYQ56 Regeneron Pharmaceuticals Inc 75886F107 42.000000000000 NS USD 34600.020000000000 1.3378781362 Long EC CORP US N 1 N N N Poseida Therapeutics Inc 549300USKSDMNGMN8V04 Poseida Therapeutics Inc 73730P108 41412.000000000000 NS USD 110570.040000000000 4.2754090616 Long EC CORP US N 1 N N N 2024-01-23 Strategic Trust /s/ Jim Niemie Strategic Trust Principal Financial Officer XXXX NPORT-EX 2 kt_xdna.htm NPORT-EX
Kelly CRISPR & Gene Editing Technology ETF
     
SCHEDULE OF INVESTMENTS
     
November 30, 2023 (Unaudited)
 
           
Number of Shares
 
 
 
Value
 
MONEY MARKET FUNDS 0.4%
     
 
4,850
 
First American Government Obligations Fund - Class X, 5.29% (a)
 
$
4,850
 
 
4,850
 
First American Treasury Obligations Fund - Class X, 5.28% (a)
   
4,849
 
           
9,699
 
     
Total Money Market Funds
       
     
(Cost $9,699)
   
9,699
 
               
     
Total Investments 0.4%
       
     
(Cost $9,699)
   
9,699
 
               
     
Other Assets in Excess of Liabilities 99.6%
   
2,573,842
 
               
     
TOTAL NET ASSETS 100.0%
 
$
2,583,541
 
   
(a) 7-day yield.
 
               

Investment Valuation
 
 
 
 
 
 
 
The net asset value (“NAV”) per share of the Kelly CRISPR & Gene Editing Technology ETF (the “Fund”) is calculated each business day as of the close of regular trading on the New York Stock Exchange (“NYSE”), generally 4:00 p.m., Eastern Time. The Fund’s NAV per share is computed by dividing the Fund’s net assets by the number of shares outstanding. When calculating the NAV of the Fund’s shares, securities held by the Fund are valued at market quotations when reliable market quotations are readily available. Exchange traded securities and instruments (including equity securities, depositary receipts and ETFs) are generally valued at the last reported sale price on the principal exchange on which such securities are traded (at the NASDAQ Official Closing Price for NASDAQ listed securities), as of the close of regular trading on the NYSE on the day the securities are being valued or, if there are no sales, at the mean of the most recent bid and asked prices. Over-the-counter (“OTC”) securities and instruments not traded on an exchange are generally valued at the last traded price. In the absence of a recorded transaction sale price or if the last sale price is unavailable, OTC securities are valued at the mean between last bid and ask, as quoted. If an ask price for an OTC security is unavailable, last bid price is used. Such valuations would typically be categorized as Level 1 or Level 2 in the fair value hierarchy described below.
               
The Board of Trustees (the”Board”) has approved valuation procedures for the Fund (the “Valuation Procedures”), which will be used for determining fair value of any Fund investments for which a market quotation is not readily available. The valuation of the Fund’s investments is performed in accordance with the principles found in Rule 2a-5 of the 1940 Act and in conjunction with FASB’s Accounting Standards Codification Topic 820, Fair Value Measurements and Disclosures. The Board has designated the Adviser as the valuation designee of the Fund. As valuation designee, the Adviser performs the fair value determination relating to any and all Fund investments, subject to the conditions and oversight requirements described in the Valuation Procedures. The Adviser may consult with representatives from outside legal counsel, or other third-party consultants in their discussions and deliberations. Fair valuations may be used in a variety of circumstances, including but not limited to, situations when the value of a security has been materially affected by events occurring after the close of the market on which such security is principally traded (such as a corporate action or other news that may materially affect the price of such security) or trading in such security has been suspended or halted. Such valuations would typically be categorized as Level 2 or Level 3 in the fair value hierarchy described below. Fair value pricing involves subjective judgments, and it is possible that a fair value determination for a security is materially different than the value that could be realized upon the sale of such security.
               
The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (1) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (2) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:

Level 1 — Unadjusted quoted prices in active markets for identical assets.
Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
Level 3 — Significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments).
               
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
   
               
The following is a summary of inputs used to value the Fund’s investments as of November 30, 2023:
           

Investments at Value
 
Level 1
   
Level 2
   
Level 3
   
Total
Money Market Funds
 
$
9,699
   
$
-
   
$
-
   
$
9,699
Total
 
$
9,699
   
$
-
   
$
-
   
$
9,699